ErbB receptors and signaling pathways in cancer
- PMID: 19208461
- DOI: 10.1016/j.ceb.2008.12.010
ErbB receptors and signaling pathways in cancer
Abstract
The ErbB receptor tyrosine kinases play important roles in normal physiology and in cancer. Epidermal growth factor receptor (EGFR) and ErbB2 in particular are mutated in many epithelial tumors, and clinical studies suggest that they play roles in cancer development and progression. These receptors have been intensely studied, not only to understand the mechanisms underlying their oncogenic potential, but also to exploit them as therapeutic _targets. ErbB receptors activate a multiplicity of intracellular pathways via their ability to interact with numerous signal transducers. Furthermore, there are now many ErbB-_targeted inhibitors used in the clinic. In this review we will concentrate on breast tumors with ERBB2 gene amplification/receptor overexpression and non-small cell lung cancer (NSCLC) with activating EGFR mutations. We will discuss data showing the important role that the PI3K/Akt pathway plays, not only in cancer development, but also in response to _targeted therapies. Finally, mechanisms contributing to resistance to ErbB-_targeted therapeutics will also be discussed.
Similar articles
-
The efficacy of ErbB receptor-_targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.Cancer Res. 2002 Jun 1;62(11):3151-8. Cancer Res. 2002. PMID: 12036928
-
Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.Cancer Res. 2005 Dec 1;65(23):11018-25. doi: 10.1158/0008-5472.CAN-05-0491. Cancer Res. 2005. PMID: 16322251
-
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.Exp Cell Res. 2005 Apr 1;304(2):604-19. doi: 10.1016/j.yexcr.2004.12.008. Epub 2005 Jan 21. Exp Cell Res. 2005. PMID: 15748904
-
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
-
_targeting the EGFR and the PKB pathway in cancer.Curr Opin Cell Biol. 2009 Apr;21(2):185-93. doi: 10.1016/j.ceb.2008.12.006. Epub 2009 Feb 11. Curr Opin Cell Biol. 2009. PMID: 19216065 Review.
Cited by
-
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.Cell Death Dis. 2013 Mar 21;4(3):e556. doi: 10.1038/cddis.2013.79. Cell Death Dis. 2013. PMID: 23519125 Free PMC article.
-
Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells.PLoS One. 2013;8(3):e55657. doi: 10.1371/journal.pone.0055657. Epub 2013 Mar 8. PLoS One. 2013. PMID: 23520446 Free PMC article.
-
An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.Oncogene. 2016 Jan 28;35(4):438-47. doi: 10.1038/onc.2015.93. Epub 2015 Apr 27. Oncogene. 2016. PMID: 25915843
-
HER3-_targeted therapeutic antibodies and antibody-drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors.Chin Med J Pulm Crit Care Med. 2023 Feb 27;1(1):11-17. doi: 10.1016/j.pccm.2022.12.001. eCollection 2023 Mar. Chin Med J Pulm Crit Care Med. 2023. PMID: 39170873 Free PMC article. Review.
-
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3. Clin Cancer Res. 2015. PMID: 25649019 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
